Have US donations in the campaign to fight malaria been responsible for saving the lives of up to two million children in Africa? Foreign aid often faces the accusation of not being cost efficient, or poorly directed. In many cases there are a lack of follow up studies analysing the impact of the donations. A study published in PLOS Medicine is … [Read more...] about US malaria donations saving two million children?
Despite months of furious debate over Brexit, few have talked about its potential implications for the pharmaceutical industry and medical research. When the UK leaves the EU, the prospects for British pharmaceuticals may be dim. This is increasingly apparent as a hard Brexit seems ever more likely, with no deal between the UK and the EU at the … [Read more...] about Brexit uncertainty, blocking both medicines and migrants?
Poverty-related and neglected diseases (PRNDs) carry high burdens of morbidity and mortality across the developing world. Some of the most common diseases within this category are malaria, HIV and tuberculosis. These diseases are endemic in impoverished and lower middle-income nations and cause considerable loss of life. A large degree of the … [Read more...] about Hyderus participates in study on whether EU funding has helped people with poverty related diseases
A revolutionary new blood test could significantly advance our capacity for detecting cancer in its early stages. CancerSEEK, developed in John Hopkins University, could improve detection methods and consequently reduce mortality rates. Cancer is often a treatable condition. However, in many cases, it does not display symptoms for many years. As … [Read more...] about Blood test to detect early stage cancer
Controversy has broken out in India regarding access to two treatments that are used to address drug resistant tuberculosis (TB). The medications, bedaquiline and delamanid are all but unavailable in India, with fewer than 1,000 DR-TB patients in India receiving bedaquiline and only 81 receive delamanid. This has led to calls for the issuing of … [Read more...] about TB ‘miracle cures’ and the issue of high expectations
India holds a unique position in the generic market. Commonly referred to as the “pharmacy of the developing world”, India exports huge volumes of generic medication. This forms a multi-billion dollar industry within India. This low cost generics market has improved access to lower price medications in India, as well as allowed for the export … [Read more...] about Indian patent laws, no longer the pharmacy of the developing world?
Early-stage human trials have shown that a potential treatment for Huntington’s disease -- devised by University College London -- is both safe and potentially effective. But is it a “breakthrough that may stop the disease” that media reports claim? Huntington's disease, as of yet, has no cure. IONIS-HTTRx, a potential cure? The potential new … [Read more...] about New hope for Huntington’s disease?
In yet another setback to the treatment of Alzheimer’s disease, Axovant Sciences has announced that their latest attempt at creating a treatment - a drug known as Intepirdine (a (5-HT)6 receptor antagonist) - has failed during late stage clinical trials. Meanwhile, pharmaceutical giant Pfizer Inc has announced plans to leave the field of … [Read more...] about Axovant fails while Pfizer leaves – the grim outlook of Alzheimer’s research
A robotic takeover has long been thought of as the stuff of nightmares, from being a staple of science fiction doomsday scenarios to being warned of by sci-tech leaders such as Elon Musk as an outcome if artificial intelligence (AI) technology continues to grow. In contrast to these bleak predictions on the future of robotics, however, the … [Read more...] about Robotic takeover of healthcare on the horizon?
Alzheimer’s research may see a well needed boost in the form of a research deal funded by Chicago based pharmaceutical group AbbVie. The recipient research group, Alector, is to receive a $205 million USD up front payment, as well as future equity investments worth up to $20 million. Alector has seen a great deal of interest within the … [Read more...] about Immunotherapy: the future of Alzheimer’s research?